Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis

Katherine B Hisert1, Timothy P Birkland1, Kelly Q Schoenfelt2

  • 1Dept of Medicine, University of Washington, Seattle, WA, USA.

ERJ Open Research
|April 28, 2020
PubMed

Insights

This study shows that starting ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, benefits individuals with cystic fibrosis. Early treatment with ivacaftor improves health outcomes for eligible patients.

Area of Science:

  • Medical Research
  • Pharmacology

Background:

  • Cystic fibrosis (CF) is a genetic disorder affecting multiple organs.
  • The cystic fibrosis transmembrane conductance regulator (CFTR) protein is crucial for ion transport.
  • Defective CFTR function leads to CF symptoms.

Purpose of the Study:

  • To evaluate the impact of initiating ivacaftor treatment in individuals with cystic fibrosis.
  • To assess the clinical benefits and outcomes associated with ivacaftor therapy.

Main Methods:

  • Observational study design.
  • Analysis of patient data following ivacaftor initiation.
  • Assessment of relevant clinical endpoints.

Main Results:

  • Initiation of ivacaftor demonstrated positive effects in people with cystic fibrosis.
  • Specific susceptible populations showed notable improvements.
  • Further details on efficacy and safety are presented.

Conclusions:

  • Ivacaftor is an effective modulator for treating cystic fibrosis in susceptible individuals.
  • Early initiation of CFTR modulator therapy can be beneficial.
  • This highlights the importance of personalized medicine in CF treatment.

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
378
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
645
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
385
Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
3.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K